"Tumor Lysis Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.
Descriptor ID |
D015275
|
MeSH Number(s) |
C15.604.515.880 C20.683.515.950
|
Concept/Terms |
Tumor Lysis Syndrome- Tumor Lysis Syndrome
- Syndrome, Tumor Lysis
- Syndromes, Tumor Lysis
- Tumor Lysis Syndromes
- Tumour Lysis Syndrome
- Syndrome, Tumour Lysis
- Syndromes, Tumour Lysis
- Tumour Lysis Syndromes
|
Below are MeSH descriptors whose meaning is more general than "Tumor Lysis Syndrome".
Below are MeSH descriptors whose meaning is more specific than "Tumor Lysis Syndrome".
This graph shows the total number of publications written about "Tumor Lysis Syndrome" by people in this website by year, and whether "Tumor Lysis Syndrome" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 1 | 0 | 1 |
2008 | 0 | 1 | 1 |
2009 | 0 | 1 | 1 |
2012 | 1 | 0 | 1 |
2013 | 1 | 0 | 1 |
2016 | 1 | 0 | 1 |
2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Lysis Syndrome" by people in Profiles.
-
Kube P, Parisio K, Mangum DS, Powell J. Fusion-negative rhabdomyosarcoma with diffuse bony metastases and remarkable chemosensitivity. BMJ Case Rep. 2022 Aug 29; 15(8).
-
Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, Callahan C, Rheingold SR, Zheng Z, Rose-John S, White JC, Nazimuddin F, Wertheim G, Levine BL, June CH, Porter DL, Grupp SA. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discov. 2016 06; 6(6):664-79.
-
Kutsch E, Kreiger P, Consolini D, Furuya KN. Colonic perforation after rituximab treatment for posttransplant lymphoproliferative disorder. J Pediatr Gastroenterol Nutr. 2013 Jun; 56(6):e41.
-
Firwana BM, Hasan R, Hasan N, Alahdab F, Alnahhas I, Hasan S, Varon J. Tumor lysis syndrome: a systematic review of case series and case reports. Postgrad Med. 2012 Mar; 124(2):92-101.
-
Karp JE, Blackford A, Smith BD, Alino K, Seung AH, Bola?os-Meade J, Greer JM, Carraway HE, Gore SD, Jones RJ, Levis MJ, McDevitt MA, Doyle LA, Wright JJ. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res. 2010 Jul; 34(7):877-82.
-
Feusner JH, Ritchey AK, Cohn SL, Billett AL. Management of tumor lysis syndrome: need for evidence-based guidelines. J Clin Oncol. 2008 Dec 01; 26(34):5657-8; author reply 5658-9.
-
Lehner SG, Gould JE, Saad WE, Brown DB. Tumor lysis syndrome after radiofrequency ablation of hepatocellular carcinoma. AJR Am J Roentgenol. 2005 Nov; 185(5):1307-9.
-
Sakarcan A, Quigley R. Hyperphosphatemia in tumor lysis syndrome: the role of hemodialysis and continuous veno-venous hemofiltration. Pediatr Nephrol. 1994 Jun; 8(3):351-3.